INTRAVESICAL CHEMOTHERAPY (MITOMYCIN-C) VERSUS IMMUNOTHERAPY (BACILLUS CALMETTE-GUERIN) IN SUPERFICIAL BLADDER-CANCER

被引：1

作者：

RINTALA, E ^{[1
]}

JAUHIAINEN, K ^{[1
]}

ALFTHAN, O ^{[1
]}

HANSSON, E ^{[1
]}

JUUSELA, H ^{[1
]}

KANERVA, K ^{[1
]}

KORHONEN, H ^{[1
]}

PERMI, J ^{[1
]}

SOTARAUTA, M ^{[1
]}

VAALASTI, T ^{[1
]}

VIITANEN, J ^{[1
]}

USENIUS, R ^{[1
]}

机构：

[1] UNIV HELSINKI,CENT HOSP,UROL CLIN,FINNBLADDER GRP,SF-00100 HELSINKI 10,FINLAND

来源：

EUROPEAN UROLOGY | 1991年 / 20卷 / 01期

关键词：

INTRAVESICAL THERAPY; SUPERFICIAL BLADDER CANCER; MITOMYCIN-C; BACILLUS CALMETTE-GUERIN;

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Both intravesical mitomycin C (MMC) and bacillus Calmette-Guerin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (T(a)-T1) bladder cancer. The result was in favour of BCG, as shown by the measurements with complete response (CR), disease-free inter-val and recurrence rate. CR of 58% with MMC and 40% with BCG were reached in 22 instillation series on carcinoma in situ of 18 patients. Due to side effects, MMC instillations were discontinued in 8.6%, and BCG instillations in 19.6%, respectively. After the 2-year follow-up also 1 case of pulmonary tuberculosis occurred in the BCG group.

引用

页码：19 / 25

页数：7

共 50 条

[21] ARTHRITIS AFTER CALMETTE-GUERIN BACILLUS IMMUNOTHERAPY FOR BLADDER-CANCER
GOUPILLE, P
SOUTIF, D
VALAT, JP
[J]. JOURNAL OF RHEUMATOLOGY, 1992, 19 (11) : 1825 - 1826
[22] SYSTEMIC BACILLUS CALMETTE-GUERIN INFECTION, BCGITIS, IN PATIENTS TREATED BY INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR BLADDER-CANCER
STEG, A
LELEU, C
DEBRE, B
BOCCONGIBOD, L
SICARD, D
[J]. EUROPEAN UROLOGY, 1989, 16 (03) : 161 - 164
[23] Polyarthritis as a complication of intravesical Bacillus Calmette-Guerin immunotherapy for bladder cancer
Onur, Ö
Çeliker, R
[J]. CLINICAL RHEUMATOLOGY, 1999, 18 (01) : 74 - 76
[24] Intravesical bacillus Calmette-Guerin combined with electromotive mitomycin for high-risk superficial bladder cancer
Bochner, Bernard H.
[J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (09): : 474 - 475
[25] Re: Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer
Maffezzini, Massimo
[J]. EUROPEAN UROLOGY, 2006, 50 (06) : 1371 - 1371
[26] BACILLUS CALMETTE-GUERIN (BCG) - MECHANISM OF ACTION IN SUPERFICIAL BLADDER-CANCER
RATLIFF, TL
[J]. UROLOGY, 1991, 37 (05) : 8 - 11
[27] MANAGEMENT OF LOCAL BACILLUS CALMETTE-GUERIN FAILURES IN SUPERFICIAL BLADDER-CANCER
KLEIN, EA
ROGATKO, A
HERR, HW
[J]. JOURNAL OF UROLOGY, 1992, 147 (03): : 601 - 605
[28] BACILLUS CALMETTE-GUERIN THERAPY ALTERS THE PROGRESSION OF SUPERFICIAL BLADDER-CANCER
HERR, HW
LAUDONE, VP
BADALAMENT, RA
OETTGEN, HF
SOGANI, PC
FREEDMAN, BD
MELAMED, MR
WHITMORE, WF
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) : 1450 - 1455
[29] 4'-EPIDOXORUBICIN VERSUS MITOMYCIN-C INTRAVESICAL CHEMOPROPHYLAXIS OF SUPERFICIAL BLADDER-CANCER
DASILVA, FC
FERRITO, F
BRANDAO, T
SANTOS, A
[J]. EUROPEAN UROLOGY, 1992, 21 (01) : 42 - 44
[30] INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT FOR SUPERFICIAL BLADDER-CANCER - RESULTS AFTER 15 YEARS OF EXPERIENCE
VANDERMEIJDEN, APM
STEERENBERG, PA
DEJONG, WH
DEBRUYNE, FMJ
[J]. ANTICANCER RESEARCH, 1991, 11 (03) : 1253 - 1258

← 1 2 3 4 5 →